Donidalorsen: 7 agencies, 2026–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused donidalorsen: all 5 decisive outcomes across 5 agencies were positive or positive with restrictions.
Every record falls within a 0.3-year window, 26 Apr 2026 to 19 Aug 2026 — a compressed review cycle.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — HAS (France), SMC (Scotland) and PHARMAC (New Zealand) among them — hold no record for donidalorsen at all.
3 distinct indication wordings are recorded for donidalorsen by the agencies that label one in English (AWMSG, NICE and PBAC).
1 of these 7 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
The systems moved almost together: all 6 agencies opened a file on donidalorsen within a year of one another, starting with NYE METODER (Norway) on 26 Apr 2026.
Activity is concentrated rather than steady: 6 of 6 dated records fall in 2026 alone.
Restriction is doing real work here: 2 of 5 decisive outcomes narrowed donidalorsen to a subgroup rather than accepting or refusing it outright, at NYE METODER (Norway) and TLV (Sweden).
7 of the 18 agencies in this archive hold a record for donidalorsen.
The full ledger for donidalorsen reads 3 recommended, 2 restricted, 1 appraised and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2026 | Hereditary angioedema | Recommended | source |
| TLV (Sweden) | 22 Jun 2026 | Dawnzera ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| ZIN (Netherlands) | 17 Jun 2026 | Advies - vergoed donidalorsen (Dawnzera®) voor de behandeling van hereditair angio-oedeem (HAE) | reimbursed | source |
| DMC (Denmark) | 29 Apr 2026 | Donidalorsen er indiceret til rutinemæssig forebyggelse af tilbagevendende anfald af hereditært angioødem (HAE) hos voks… | Direkte indplacering | source |
| NYE METODER (Norway) | 26 Apr 2026 | Rutinemessig forebygging av residiverende anfall av hereditært angioødem (HAE) hos pasienter ≥12 år. | introduced with conditions | source |
2 further decisions for donidalorsen, across 2 agencies, are not shown here. They include the most recent record on file, 19 Aug 2026 from NICE (England); its outcome is in the subscriber dataset. They link to 2 further source documents.
Related molecules
- lanadelumab — same ATC class B06A — Other hematological agents
- exagamglogene autotemcel — same ATC class B06A — Other hematological agents
- icatibant — same ATC class B06A — Other hematological agents
- berotralstat — same ATC class B06A — Other hematological agents
- garadacimab — same ATC class B06A — Other hematological agents
- conestat alfa — same ATC class B06A — Other hematological agents
Coverage: 7 decisions for donidalorsen from 7 agencies, 2026 to 2026. Data to 7 Sep 2026. ATC class B06A — Other hematological agents. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.